BR112022011364A2 - Compostos para tratar disautonomia familiar - Google Patents
Compostos para tratar disautonomia familiarInfo
- Publication number
- BR112022011364A2 BR112022011364A2 BR112022011364A BR112022011364A BR112022011364A2 BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2 BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- dysautonomia
- family
- treat
- present disclosure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 title abstract 2
- 208000019479 dysautonomia Diseases 0.000 title abstract 2
- 208000018290 primary dysautonomia Diseases 0.000 title abstract 2
- 208000001730 Familial dysautonomia Diseases 0.000 abstract 1
- 201000001638 Riley-Day syndrome Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
COMPOSTOS PARA TRATAR DISAUTONOMIA FAMILIAR. A presente descrição se refere a compostos úteis para aprimorar splicing de pré-mRNA em uma célula. Em particular, outro aspecto da presente descrição se refere a compostos de tieno[3,2-d]pirimidina substituídos, formas e composições farmacêuticas dos mesmos, e métodos de uso para tratar ou melhorar disautonomia familiar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947049P | 2019-12-12 | 2019-12-12 | |
| PCT/US2020/063612 WO2021118929A1 (en) | 2019-12-12 | 2020-12-07 | Compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011364A2 true BR112022011364A2 (pt) | 2022-08-23 |
Family
ID=74046197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011364A BR112022011364A2 (pt) | 2019-12-12 | 2020-12-07 | Compostos para tratar disautonomia familiar |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230057568A1 (pt) |
| EP (1) | EP4072677A1 (pt) |
| JP (1) | JP2023506488A (pt) |
| KR (1) | KR20220113700A (pt) |
| CN (1) | CN115209955A (pt) |
| AU (1) | AU2020402717A1 (pt) |
| BR (1) | BR112022011364A2 (pt) |
| CA (1) | CA3160053A1 (pt) |
| CL (1) | CL2022001523A1 (pt) |
| CO (1) | CO2022008195A2 (pt) |
| IL (1) | IL293764A (pt) |
| MX (1) | MX2022007094A (pt) |
| PE (1) | PE20221581A1 (pt) |
| WO (1) | WO2021118929A1 (pt) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1028964A1 (en) * | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| WO2005007083A2 (en) * | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| WO2012030894A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| EA037663B1 (ru) | 2015-01-16 | 2021-04-28 | Те Дженерал Хоспитал Корпорейшн | СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| EP3583951A4 (en) * | 2017-02-20 | 2021-05-05 | Kyoto University | PHARMACEUTICAL COMPOSITION AND TREATMENT METHODS FOR GENETIC DISEASES ASSOCIATED WITH SPICE ANOMALIES |
| WO2020167624A1 (en) * | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
-
2020
- 2020-12-07 CN CN202080096472.5A patent/CN115209955A/zh active Pending
- 2020-12-07 AU AU2020402717A patent/AU2020402717A1/en active Pending
- 2020-12-07 WO PCT/US2020/063612 patent/WO2021118929A1/en unknown
- 2020-12-07 EP EP20829474.4A patent/EP4072677A1/en active Pending
- 2020-12-07 BR BR112022011364A patent/BR112022011364A2/pt not_active Application Discontinuation
- 2020-12-07 IL IL293764A patent/IL293764A/en unknown
- 2020-12-07 KR KR1020227019352A patent/KR20220113700A/ko active Search and Examination
- 2020-12-07 US US17/783,941 patent/US20230057568A1/en active Pending
- 2020-12-07 CA CA3160053A patent/CA3160053A1/en active Pending
- 2020-12-07 PE PE2022001057A patent/PE20221581A1/es unknown
- 2020-12-07 MX MX2022007094A patent/MX2022007094A/es unknown
- 2020-12-07 JP JP2022535707A patent/JP2023506488A/ja active Pending
-
2022
- 2022-06-09 CL CL2022001523A patent/CL2022001523A1/es unknown
- 2022-06-10 CO CONC2022/0008195A patent/CO2022008195A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001523A1 (es) | 2023-03-31 |
| PE20221581A1 (es) | 2022-10-06 |
| WO2021118929A1 (en) | 2021-06-17 |
| US20230057568A1 (en) | 2023-02-23 |
| EP4072677A1 (en) | 2022-10-19 |
| MX2022007094A (es) | 2022-07-11 |
| CA3160053A1 (en) | 2021-06-17 |
| JP2023506488A (ja) | 2023-02-16 |
| CO2022008195A2 (es) | 2022-07-29 |
| AU2020402717A1 (en) | 2022-06-23 |
| KR20220113700A (ko) | 2022-08-16 |
| IL293764A (en) | 2022-08-01 |
| CN115209955A (zh) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002137A1 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| BR112012012815A8 (pt) | composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica | |
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
| BRPI1006602A2 (pt) | composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição | |
| BR112018000808A2 (pt) | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase | |
| BR112019007144A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
| BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
| MY197635A (en) | Benzooxazole derivatives as immunomodulators | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| EA201790267A1 (ru) | Новые модуляторы киназ | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| BR112013002484A2 (pt) | composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto. | |
| BR112016024626A8 (pt) | compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet | |
| BRPI0720569B8 (pt) | compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária | |
| CR20160170A (es) | Moduladores del factor del complemento b | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| EA201201191A1 (ru) | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций | |
| BRPI0811816A2 (pt) | "forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem" | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| BR112022001161A2 (pt) | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |